Table 3.

Characteristics of all CLL patients using IGHV3-21 gene




Total

France

Greece

Italy

Spain
No. IGHV3-21 cases   16   4   7   4   1  
Frequency, %   2.9   2.7   3.7   4.1   0.9  
Mean age, y   70.7   63.5   67   79.5   90* 
Sex, no. F/no. M   8/8   2/2   4/3   1/3   1/0  
No. mutated/no. unmutated   7/9   2/2   2/5   2/2   1/0  
IGHV homology, no.      
At least 98%   9   2   5   2   0  
98%-96%   3   0   1   1   1  
Less than 96%   4   2   1   1   0  
LC, no. κ/no. λ   7/9   2/2   4/3   1/3   0/1  
IGV LC homology, no.      
At least 98%   14   3   7   3   1  
98%-96%   2   1   0   1   0  
Less than 96%   0   0   0   0   0  
CD38, %      
Neg   5   0   4   1   0  
Pos   10   3   3   3   1  
Stage at diagnosis      
A   8   1   5   2   0  
B   5   3   1   1   0  
C   3   0   1   1   1  
Clinical course      
Stable   5   0   4   1   0  
Progressive   11   4   3   3   1  
Need for treatment   11   4   3   3   1  
CLL-related death
 
4
 
2
 
0
 
1
 
1
 



Total

France

Greece

Italy

Spain
No. IGHV3-21 cases   16   4   7   4   1  
Frequency, %   2.9   2.7   3.7   4.1   0.9  
Mean age, y   70.7   63.5   67   79.5   90* 
Sex, no. F/no. M   8/8   2/2   4/3   1/3   1/0  
No. mutated/no. unmutated   7/9   2/2   2/5   2/2   1/0  
IGHV homology, no.      
At least 98%   9   2   5   2   0  
98%-96%   3   0   1   1   1  
Less than 96%   4   2   1   1   0  
LC, no. κ/no. λ   7/9   2/2   4/3   1/3   0/1  
IGV LC homology, no.      
At least 98%   14   3   7   3   1  
98%-96%   2   1   0   1   0  
Less than 96%   0   0   0   0   0  
CD38, %      
Neg   5   0   4   1   0  
Pos   10   3   3   3   1  
Stage at diagnosis      
A   8   1   5   2   0  
B   5   3   1   1   0  
C   3   0   1   1   1  
Clinical course      
Stable   5   0   4   1   0  
Progressive   11   4   3   3   1  
Need for treatment   11   4   3   3   1  
CLL-related death
 
4
 
2
 
0
 
1
 
1
 
*

Actual age of the single patient of the Spanish series.

Close Modal

or Create an Account

Close Modal
Close Modal